Phase 1 trial of CAT-4001 in patients with Friedreich's ataxia and Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

Phase 1 trial of CAT-4001 in patients with Friedreich's ataxia and Amyotrophic Lateral Sclerosis (ALS)

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Docosahexaenoic acid-citraconic acid conjugate (Primary)
  • Indications Amyotrophic lateral sclerosis; Friedreich's ataxia
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Mar 2016 New trial record
    • 02 Mar 2016 According to Catabasis media release, company is planning to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top